UK drugmaker signs agreement with China’s Eccogene to work on an obesity and type 2 diabetes pill
AstraZeneca is making a big push into the weight-loss drug market, striking an exclusive licence agreement with a Chinese company for an obesity and type 2 diabetes pill that is in early stage development.
Britain’s biggest drugmaker said it had agreed a deal with Eccogene, based in Shanghai, for an experimental drug named ECC5004 that would also treat other cardiometabolic conditions such as heart disease and stroke. Eccogene will receive up to $2bn under the terms of the deal.
About Author
More Stories
Former bosses at video games firm Ubisoft on trial in France accused of sexual harassment
High-rise, high expectations: is Casablanca’s finance hub a model for African development?
China accuses US of ‘seriously violating’ trade truce